Objective: To evaluate the clinical efficacy and safety of rifaximin capsula for acute infectious entercolitis. Methods:A total of 216 patients with acute infectious entercolitis entered a randomized controlled double-blind double dummy multicenter clinical trial. Patients were divided into two groups treated with rifaximin capsula（200 mg, per 6 h）+Oflxacin dummy capsula（2#，3 times per day） as a treated group and Oflaxaxin（200 mg, three times per day）+ rifaxicin dummy capsula（2#, per 6 h) as a control for three days, respectively. 109 patients were enrolled in rifaximin group and 107 patients were enrolled in control group. Results:The rate and time of diarrhea, the normalization rate of stool routine, the clearance of bacteria and the relieve rate of symptoms were similar in the two groups. The total efficacy rates were 95.41% and 95.33%in the treatment and controlled group, respectively. The incidence of adverse reaction was 3.64% and 2.75% in the two groups. There werer no significant differences between the two groups in total efficacy and incidence of adverse reaction. Conclision:Rifaximin is effective and safe in the treatment of acute infectious entercolitis.